Clinical pharmacological trial of TM8001 for schizophrenia associated with carbonyl stress

Phase 2

• Conditions: schizophrenia associated with carbonyl stress

• Registration Number: JPRN-UMIN000006398
• Lead Sponsor: Tokyo Metropolitan Matsuzawa Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-10-01
• Study Completion: 2012-04-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Not provided

Exclusion Criteria

creatinin >2mg/dL or BUN > 25mg/dL. HbA1c > 6.1% and fetal blood suger > 126mg/dL or blood suger > 200mg/dL. AST, ALT over 2.5 fold of standard level. Total bilirubin > 3mg/dL. sever cardiac diseases, lung diseases, hepatic diseases, neurological diseases, hematological diseases, endocrine diseases,immune diseases, other sever diseases. History of anaphylaxis shock, drug allergy. History of taking aminophylline , teophylline, cholinteophylline, levodopa within 4 weeks before trail. History of taking ECT within 3 months before trail. Possible risk of suicide. History of cancer within 5 years before trail. Participating other trial. Pregnancy. Inappropriate regarded by the responsible doctor.

Study & Design

• Study Type: Interventional
• Study Design: Not specified